141 related articles for article (PubMed ID: 25368012)
41. Reply to M.G. McNamara et al and M.S. Copur et al.
Domchek SM; Kaufman B; Friedlander M
J Clin Oncol; 2015 Aug; 33(23):2583-4. PubMed ID: 26124483
[No Abstract] [Full Text] [Related]
42. Olaparib effective in four advanced cancers.
Cancer Discov; 2015 Jan; 5(1):OF3. PubMed ID: 25583815
[TBL] [Abstract][Full Text] [Related]
43. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
44. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors.
Veeck J; Ropero S; Setien F; Gonzalez-Suarez E; Osorio A; Benitez J; Herman JG; Esteller M
J Clin Oncol; 2010 Oct; 28(29):e563-4; author reply e565-6. PubMed ID: 20679605
[No Abstract] [Full Text] [Related]
45. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
[TBL] [Abstract][Full Text] [Related]
46. Olaparib, PARP1 inhibitor in ovarian cancer.
Marchetti C; Imperiale L; Gasparri ML; Palaia I; Pignata S; Boni T; Bellati F; Benedetti Panici P
Expert Opin Investig Drugs; 2012 Oct; 21(10):1575-84. PubMed ID: 22788971
[TBL] [Abstract][Full Text] [Related]
47. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
48. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
49. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
50. The long and winding road.
DenBrok W; Simmons C; Gelmon KA
J Clin Oncol; 2015 Jan; 33(3):229-31. PubMed ID: 25452438
[No Abstract] [Full Text] [Related]
51. To BRCA or Not to PALB.
McNamara MG; Lamarca A; Hubner RA; Valle JW
J Clin Oncol; 2015 Aug; 33(23):2581-2. PubMed ID: 26124473
[No Abstract] [Full Text] [Related]
52. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
Sahin I; Ararat E; Altundag K
J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
[No Abstract] [Full Text] [Related]
53. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
54. PARP inhibition in BRCA-mutated breast and ovarian cancers.
Chan SL; Mok T
Lancet; 2010 Jul; 376(9737):211-3. PubMed ID: 20656109
[No Abstract] [Full Text] [Related]
55. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Kruse V; Rottey S; De Backer O; Van Belle S; Cocquyt V; Denys H
Acta Clin Belg; 2011; 66(1):2-9. PubMed ID: 21485757
[TBL] [Abstract][Full Text] [Related]
56. [Olaparib in ovarian cancer with BRCA mutation].
Pujade-Lauraine É; Combe P
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
[TBL] [Abstract][Full Text] [Related]
57. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
58. [PARP inhibitors to treat triple negative breast cancer].
Sugie T
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2850-5. PubMed ID: 21235091
[No Abstract] [Full Text] [Related]
59. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
60. Out of the frying pan, into the fire.
Prescrire Int; 2017 Jan; 26(178):4. PubMed ID: 30730632
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
